The DOI matches its Crossref record.
Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis
Abstract
Objective: To compare work disability and job loss in early rheumatoid arthritis (RA) patients receiving adalimumab plus methotrexate (adalimumab + MTX) versus MTX alone. Methods: In this multicenter, randomized, controlled trial, patients with RA for <2 years who had never taken MTX and who self‐reported work impairment were randomized to adalimumab + MTX or placebo + MTX for 56 weeks. Primary outcome was job loss of any cause and/or imminent job loss at or after week 16. Secondary outcomes included disease activity, function (Health Assessment Questionnaire [HAQ] score), and RA quality of life (RAQoL) questionnaire score. Work was evaluated with work diaries and the RA Work Instability Scale. Results: Although job loss during the 56‐week study was significantly lower with adalimumab + MTX (14 of 75 patients) compared with MTX alone (29 of 73 patients; P = 0.005), the primary end point was not met (12 of 75 versus 20 of 73 patients; P = 0.092), likely owing to early drop out in the MTX group. There were significant improvements in American College of Rheumatology 20% response criteria, 28‐joint Disease Activity Score, ΔHAQ, ΔRAQoL, and working time lost in the adalimumab + MTX group. Twenty‐four serious adverse events were reported in 17 participants, with no differences between groups. Conclusion: Adalimumab + MTX reduced job loss and improved productivity in early RA when compared with MTX alone, which supports the early use of anti–tumor necrosis factor therapy and suggests its cost efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 25
- 10.1136/ard.61.4.335 · DOI · Paper page
- 10.1002/art.20419 · DOI · Paper page
- 10.1002/art.21326 · DOI
- Backman CL, 2004, Participation in paid and unpaid work by adults with rheumatoid arthritis, J Rheumatol, 31, 47
- Guillemin F, 2004, Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital‐based rheumatologists, J Rheumatol, 31, 1297
- 10.1056/NEJM200011303432201 · DOI · Paper page
- 10.1136/ard.2003.013961 · doi:10.1136/ard.2003.013961
- 10.1002/art.21405 · DOI · Paper page
- 10.1136/bmj.39265.679375.80 · doi:10.1136/bmj.39265.679375.80
- Quinn MA, 2001, Job loss increases in early RA despite control of disease activity: results from a large secondary care multi‐centre study using step‐up combination therapy, Arthritis Rheum, 44, S378
- 10.1002/art.11114 · DOI · Paper page
- 10.1136/ard.60.11.1025 · DOI
- Walker N, 2005, Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients, J Rheumatol, 32, 1006
- 10.1002/art.11285 · DOI
- 10.1002/art.21661 · doi:10.1002/art.21661
- 10.1002/art.1780310302 · DOI · Paper page
- 10.1002/art.1790050303 · DOI · Paper page
- De Jong Z, 1995, Development and validation of a RA‐specific quality of life measure (RAQoL), Arthritis Rheum, 38, S175
- 10.1093/rheumatology/40.10.1112 · DOI
- 10.1002/art.1780380107 · DOI · Paper page
- 10.1093/rheumatology/keh324 · doi:10.1093/rheumatology/keh324
- 10.7326/0003-4819-93-4-551 · DOI · Paper page
- 10.1002/art.20712 · DOI · Paper page
- 10.1002/art.20568 · DOI · Paper page
- 10.1002/art.21519 · DOI · Paper page
Cited by
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126573 · Cited by 406
Self-citationAnti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
Taylor, P. C., & Feldmann, M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.181 · Cited by 389
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Lopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Metadata
- Authors
- Bejarano, V., Quinn, M., Conaghan, P. G., Reece, R., Keenan, A., Walker, D., Gough, A., Green, M., McGonagle, D., Adebajo, A., Jarrett, S., Doherty, S., Hordon, L., Melsom, R., Unnebrink, K., Kupper, H., & Emery, P.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2008-09-29
- Volume
- 59
- Issue
- 10
- Pages
- 1467-1474
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W2072599775
- Cited by
- 174
- References
- 0
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.24106
- The paper
- Bejarano, V., Quinn, M., Conaghan, P. G., Reece, R., Keenan, A., Walker, D., Gough, A., Green, M., McGonagle, D., Adebajo, A., Jarrett, S., Doherty, S., Hordon, L., Melsom, R., Unnebrink, K., Kupper, H., & Emery, P. (2008). Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Care & Research. https://doi.org/10.1002/art.24106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.